Promoting Recovery After STroke With Amantadine

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT05140148
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Stroke Hemorrhagic
  • Stroke, Ischemic

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Amantadine — DRUG
    Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease
  • Placebo — DRUG
    placebo pills

Study Details

The investigators aim to examine whether amantadine can help patients recover from stroke. This will be a blinded randomized clinical trial (RCT). Patients will be randomized post-ischemic or hemorrhagic stroke either to the placebo arm or amantadine arm. Patients will be on study drug or placebo for 1 month but will be enrolled for 3 months total. At various time points patients will be examined and fill out questionnaires to determine level of stroke recovery.

Key Dates

Start date
Feb 1, 2022
Status verified
Mar 2026
Primary completion
Dec 31, 2027
Completion
Jun 30, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo
    placebo pill, twice daily
  • Active Comparator: Amantadine
    100 mg amantadine twice daily, or if 65 years or older once daily

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Day 90 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The Hospital of the University of PennsylvaniaPhiladelphiaPennsylvania19104
Nichole Gallatti
[email protected]
Scott Kasner, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By research site
The Hospital of the University of Pennsylvania· Philadelphia, PA

Related Studies